ConTIPI Medical Ltd., 2 Alon Hatavor st., 3088900, Caesarea, Israel.
BMC Womens Health. 2022 Nov 18;22(1):459. doi: 10.1186/s12905-022-02057-6.
We evaluated a novel disposable, collapsible, ring-shaped vaginal device that is self-inserted within an applicator and removed with a string. The device was developed to overcome the drawbacks of existing ring pessaries for non-surgical pelvic organ prolapse management (POP).
The primary objective efficacy endpoint of this prospective, interventional, multicenter, self-controlled, and home-use study was the proportion of subjects with improved staging on the Pelvic Organ Prolapse Quantification (POP-Q) scale. Subjective efficacy was assessed using the POP symptoms alleviation score. Safety was evaluated by recording the rate and incidence of adverse events (AEs) in a daily diary, and quality of life (QoL) was evaluated using the modified Pelvic Floor Impact (PFIQ-7) and Pelvic Floor Disability Index (PFDI-20) questionnaires.
A total of 94 usage cycles were observed in a group of 52 participants (mean age 60.2 ± 10.5 years, 81.1% postmenopausal) who used the device for 3558 days. Of these, 24 participants completed one usage cycle, 14 completed two usage cycles, and 14 completed three usage cycles with 28-45 days of ProVate use in each usage cycle. All patients experienced greater than two POP-Q stage reductions. The descent was completely reduced to POP-Q stage 0 in 97.8% of participants. The POP symptom alleviation questionnaire showed significant subjective efficacy (P < 0.0001). The modified PFDI-20 and PFIQ-7 scores also improved substantially (P < 0.0001 for both). There were 91 nonserious device-related AEs: 98.9% were mild and 87.9% anticipated, with no vaginal infection, and one case of urinary tract infection.
The novel device substantially reduces prolapse and provides significant subjective POP symptom relief and QoL improvement, with minimal AEs. The device may enable women to self-manage their prolapse with a small, disposable device that minimizes self-touching and frequent dependency on the clinic.
Clinical.
gov , NCT02239133 , posted September 12, 2014 (retrospectively registered).
我们评估了一种新型的一次性、可折叠、环形阴道装置,该装置可自行插入给药器内,然后通过绳子取出。该装置旨在克服现有环形子宫托在非手术治疗盆腔器官脱垂(POP)方面的缺陷。
这项前瞻性、介入性、多中心、自我对照、家庭使用研究的主要疗效终点是采用盆腔器官脱垂量化(POP-Q)量表评估的患者分期改善比例。通过 POP 症状缓解评分评估主观疗效。通过日常日记记录不良事件(AE)的发生率和发生率来评估安全性,并采用改良盆腔底部冲击力问卷(PFIQ-7)和盆腔底部残疾指数(PFDI-20)问卷评估生活质量(QoL)。
52 名参与者(平均年龄 60.2±10.5 岁,81.1%绝经后)共观察到 94 个使用周期,每个使用周期使用 ProVate 28-45 天,使用该装置 3558 天。其中,24 名参与者完成了一个使用周期,14 名参与者完成了两个使用周期,14 名参与者完成了三个使用周期。所有患者的 POP-Q 分期均有大于两期的改善。97.8%的患者完全降低到 POP-Q 分期 0。POP 症状缓解问卷显示出显著的主观疗效(P<0.0001)。改良后的 PFDI-20 和 PFIQ-7 评分也有显著提高(均 P<0.0001)。共发生 91 例与器械相关的非严重不良事件:98.9%为轻度,87.9%为预期,无阴道感染,1 例尿路感染。
该新型装置可显著减少脱垂,显著缓解 POP 症状,提高生活质量,且不良事件较少。该装置可能使女性能够通过一种小型、一次性的装置来自我管理脱垂,从而减少自我触摸和对诊所的频繁依赖。
临床.gov,NCT02239133,2014 年 9 月 12 日(回溯注册)。